BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 28262583)

  • 1. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
    Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
    Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
    Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY
    Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.
    Chi EA; Schweizer MT
    Clin Genitourin Cancer; 2017 Oct; 15(5):e855-e857. PubMed ID: 28465048
    [No Abstract]   [Full Text] [Related]  

  • 5. Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.
    Oing C; Bokemeyer C
    Curr Opin Urol; 2018 Sep; 28(5):479-484. PubMed ID: 29957683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
    Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
    Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
    Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors.
    Zschäbitz S; Lasitschka F; Jäger D; Grüllich C
    Ann Oncol; 2016 Jul; 27(7):1356-60. PubMed ID: 27029705
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
    N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
    Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
    J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
    Calaminus G; Schneider DT; Weissbach L; Schönberger S; Okpanyi V; Leuschner I; Poremba C; Göbel U
    Klin Padiatr; 2009; 221(3):136-40. PubMed ID: 19437360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
    Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
    Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
    J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [High dose chemotherapy with autologous stem-cell support in germ cell tumors: The Instituto Português de Oncologia de Lisboa Francisco Gentil Series].
    Brito M; Sanchez P; Velho S; Miranda N; Leal da Costa F; Ferreira I; Teixeira G; Guimarães A; Abecasis M; Passos Coelho JL
    Acta Med Port; 2011; 24(4):533-44. PubMed ID: 22521011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
    Fléchon A; Biron P; Philip I; Blay JY; Droz JP
    Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
    Lotz JP; Bui B; Gomez F; Théodore C; Caty A; Fizazi K; Gravis G; Delva R; Peny J; Viens P; Duclos B; De Revel T; Curé H; Gligorov J; Guillemaut S; Ségura C; Provent S; Droz JP; Culine S; Biron P;
    Ann Oncol; 2005 Mar; 16(3):411-8. PubMed ID: 15659420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
    Rick O; Siegert W; Beyer J
    Cancer Treat Rev; 2001 Oct; 27(5):283-8. PubMed ID: 11871864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial.
    Lorch A; Kleinhans A; Kramar A; Kollmannsberger CK; Hartmann JT; Bokemeyer C; Rick O; Beyer J
    J Clin Oncol; 2012 Mar; 30(8):800-5. PubMed ID: 22291076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.